DrugCite
Search

EMTRIVA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Emtriva Adverse Events Reported to the FDA Over Time

How are Emtriva adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Emtriva, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Emtriva is flagged as the suspect drug causing the adverse event.

Most Common Emtriva Adverse Events Reported to the FDA

What are the most common Emtriva adverse events reported to the FDA?

Drug Exposure During Pregnancy
37 (1.88%)
Renal Failure Acute
34 (1.73%)
Pyrexia
33 (1.68%)
Immune Reconstitution Syndrome
30 (1.53%)
Stillbirth
28 (1.42%)
Anaemia
26 (1.32%)
Diarrhoea
24 (1.22%)
Abortion Spontaneous
23 (1.17%)
Blood Creatinine Increased
23 (1.17%)
Pregnancy
20 (1.02%)
Nausea
19 (.97%)
Show More Show More
Vomiting
17 (.86%)
Dehydration
16 (.81%)
Haemoglobin Decreased
15 (.76%)
Ventricular Septal Defect
15 (.76%)
Asthenia
14 (.71%)
Cholestasis
13 (.66%)
Drug Interaction
13 (.66%)
Pre-eclampsia
13 (.66%)
Rash
13 (.66%)
Renal Failure
13 (.66%)
Thrombocytopenia
13 (.66%)
Alanine Aminotransferase Increased
12 (.61%)
Cytolytic Hepatitis
12 (.61%)
Hypoplastic Right Heart Syndrome
11 (.56%)
Lactic Acidosis
11 (.56%)
Back Pain
10 (.51%)
Blood Bilirubin Increased
10 (.51%)
Fall
10 (.51%)
Fatigue
10 (.51%)
Pneumonia
10 (.51%)
Aspartate Aminotransferase Increase...
9 (.46%)
Blood Alkaline Phosphatase Increase...
9 (.46%)
Convulsion
9 (.46%)
Hypoglycaemia
9 (.46%)
Medication Error
9 (.46%)
Oedema Peripheral
9 (.46%)
Stevens-johnson Syndrome
9 (.46%)
Confusional State
8 (.41%)
Dyspnoea
8 (.41%)
Ileus Paralytic
8 (.41%)
Pancreatitis Acute
8 (.41%)
Pericardial Effusion
8 (.41%)
Pruritus
8 (.41%)
Rash Maculo-papular
8 (.41%)
Splenomegaly
8 (.41%)
Vaginal Haemorrhage
8 (.41%)
Activated Partial Thromboplastin Ti...
7 (.36%)
Arthralgia
7 (.36%)
Blood Cholesterol Increased
7 (.36%)
Bone Marrow Failure
7 (.36%)
Congenital Tricuspid Valve Stenosis
7 (.36%)
General Physical Health Deteriorati...
7 (.36%)
Haematocrit Decreased
7 (.36%)
Hepatic Steatosis
7 (.36%)
Hypertension
7 (.36%)
Hyponatraemia
7 (.36%)
Pancreatitis
7 (.36%)
Subdural Haematoma
7 (.36%)
Weight Decreased
7 (.36%)
Aphasia
6 (.31%)
Condition Aggravated
6 (.31%)
Congenital Tricuspid Valve Atresia
6 (.31%)
Drug Ineffective
6 (.31%)
Drug Resistance
6 (.31%)
Foetal Cardiac Disorder
6 (.31%)
Hepatomegaly
6 (.31%)
Hepatotoxicity
6 (.31%)
Multi-organ Failure
6 (.31%)
Osteoporosis
6 (.31%)
Photosensitivity Reaction
6 (.31%)
Premature Rupture Of Membranes
6 (.31%)
Pulmonary Embolism
6 (.31%)
Renal Tubular Disorder
6 (.31%)
Spina Bifida
6 (.31%)
Abortion Induced
5 (.25%)
Agitation
5 (.25%)
Anorexia
5 (.25%)
Ascites
5 (.25%)
Balance Disorder
5 (.25%)
Blood Glucose Increased
5 (.25%)
Blood Triglycerides Increased
5 (.25%)
Brain Stem Syndrome
5 (.25%)
Bronchitis
5 (.25%)
Candidiasis
5 (.25%)
Central Pontine Myelinolysis
5 (.25%)
Cerebellar Syndrome
5 (.25%)
Chills
5 (.25%)
Depression
5 (.25%)
Diplegia
5 (.25%)
Drug Rash With Eosinophilia And Sys...
5 (.25%)
Dysarthria
5 (.25%)
Fanconi Syndrome
5 (.25%)
Gamma-glutamyltransferase Increased
5 (.25%)
Gastrointestinal Haemorrhage
5 (.25%)
Headache
5 (.25%)
Hepatic Failure
5 (.25%)
Hyperlactacidaemia
5 (.25%)
Hypokalaemia
5 (.25%)
Hypotension
5 (.25%)
Insomnia
5 (.25%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Emtriva, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Emtriva is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Emtriva

What are the most common Emtriva adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Emtriva, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Emtriva is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Emtriva According to Those Reporting Adverse Events

Why are people taking Emtriva, according to those reporting adverse events to the FDA?

Hiv Infection
449
Acquired Immunodeficiency Syndrome
21
Drug Use For Unknown Indication
20
Antiretroviral Therapy
20
Drug Exposure During Pregnancy
10
Product Used For Unknown Indication
6
Show More Show More
Hiv Test
3
Dialysis
3
Asymptomatic Hiv Infection
2
Prophylaxis Against Hiv Infection
2
Immunodeficiency
1
Hiv Antibody Positive
1
Antiviral Prophylaxis
1
Hiv Infection Cdc Category C3
1
Hepatitis B
1

Drug Labels

LabelLabelerEffective
EmtrivaExcella GmbH01-JUL-09
EmtrivaState of Florida DOH Central Pharmacy10-MAY-10
EmtrivaPhysicians Total Care, Inc.16-FEB-12
EmtrivaGilead Sciences, Inc.07-NOV-12

Emtriva Case Reports

What Emtriva safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Emtriva. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Emtriva.